2-氨基-5-正丙基噻唑 | 39136-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氨基-5-正丙基噻唑
• 中文别名: 5-丙基噻唑-2-胺
• 英文名称: 5-propylthiazol-2ylamine
• 英文别名: 5-propylthiazol-2-amine；5-propyl-thiazol-2-ylamine；5-Propyl-thiazol-2-ylamin；5-propyl-2-thiazolamine；2-amino-5n-propyl-thiazole；2-amino-5-propylthiazole；5-propyl-1,3-thiazol-2-amine
• CAS: 39136-61-3
• 化学式: C₆H₁₀N₂S
• mdl: MFCD00613424
• 分子量: 142.225
• InChiKey: WURBKTNKFMMSGZ-UHFFFAOYSA-N

物化性质

• 熔点：
  57-58 °C(Solv: ligroine (8032-32-4))
• 沸点：
  147-148 °C(Press: 16 Torr)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-氨基-5-正丙基噻唑 在 盐酸 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 2-Propyl-6-thiophen-3-ylimidazo[2,1-b][1,3]thiazole
  参考文献：
  名称：

  6-Thienyl and 6-phenylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH dehydrogenase

  摘要：

  Starting from the potent inhibitory effect of the previously described 2 methyl-6-(2-thienyl)imidazo[2,1-b]thiazol on mitochondrial complex I, we prepared a series of derivatives in order to study the effect of a different substitution at the positions 2, 5 and 6. The replacement of the thienyl group at position 6 with a phenyl group does not modify the biological behaviour of the lead compound, whereas the shift of the methyl group from position 2 to position 5 yields a compound devoid of inhibitory effects. In both the 6-thienyl and 6-phenyl series, the lengthening of the chain at position 2 has provided useful information to outline the structural determinants of the ubiquinone antagonist action in imidazothiazole derivatives. (C) 1999 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(99)00203-2
• 作为产物：
  描述：

  正戊醛 在 5,5-二溴-2,2-二甲基-4,6-二酮-1,3-二氧杂环己烷 、 溴 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 6.0h， 生成 2-氨基-5-正丙基噻唑
  参考文献：
  名称：

  NOVEL KINASE INHIBITORS

  摘要：

  本发明提供了噻唑基氨基取代杂环化合物的衍生物。这些化合物是激酶抑制剂，包括对细胞表现出抗增殖活性的化合物，包括对肿瘤细胞的抗活性，并且在治疗包括癌症在内的疾病方面是有用的。

  公开号：

  EP2719696A1

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Florjancic S. Alan

  公开号：US20080058335A1

  公开（公告）日：2008-03-06

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , and L 1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1a , R 2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1 ，R 2 ，R 3 和L 1 在规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1a ，R 2a 和(Rx)n如规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009067613A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物，式(I)。其中R1、R2、R3、R4和L1在规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物，式(II)。其中R1a、R2a、Rx和n如规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• 1-Oxo-1H-thiazolo[3,2-a]pyrimidine-2-carboxamides
  申请人：Pfizer Inc.

  公开号：US04414388A1

  公开（公告）日：1983-11-08

  Antiallergy and antiulcer agents having the formula (I), ##STR1## and their pharmaceutically acceptable salts, wherein R.sub.1 and R.sub.2 taken separately are each hydrogen or lower alkyl; and R.sub.1 and R.sub.2 taken together are alkylene of 3-9 carbon atoms or phenylalkylene of 9-11 carbon atoms, with the proviso that the ring so formed is between 5- and 8-membered; acids of the formula (II), ##STR2## wherein R.sub.1 and R.sub.2 are as defined above and R.sub.3 is hydrogen, which are useful as intermediates for compounds of the formula (I), but in many instances also possess the same useful biological activity as do formula I compounds; and intermediates of the formula II wherein R.sub.1 and R.sub.2 are defined as above, and R.sub.3 is alkyl of 1 to 4 carbon atoms, carbalkoxy of 2 to 5 carbon atoms, carbophenoxy or carbobenzoxy, are also described.

  抗过敏和抗溃疡药物具有以下式(I)的结构，及其药学上可接受的盐，其中R.sub.1和R.sub.2分别为氢或较低的烷基；R.sub.1和R.sub.2一起为3-9个碳原子的烷基或9-11个碳原子的苯基烷基，但所形成的环在5-至8-成员之间；式(II)的酸，其中R.sub.1和R.sub.2如上定义，R.sub.3为氢，这些酸是化合物(I)的中间体，但在许多情况下也具有与化合物I相同的有用生物活性；以及式(II)的中间体，其中R.sub.1和R.sub.2如上定义，R.sub.3为1至4个碳原子的烷基，2至5个碳原子的羰基烷基，羰基苯氧基或羰基苯甲氧基。
• 4-Hydroxy-2H-[1]-benzothieno
  申请人：Boehringer Ingelheim GmbH

  公开号：US04259336A1

  公开（公告）日：1981-03-31

  Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, halogen or alkyl of 1 to 3 carbon atoms; R.sub.2 is hydrogen or alkyl of 1 to 3 carbon atoms; and R.sub.3 is aromatic hydrocarbyl of 6 to 10 carbon atoms or an aromatic heterocycle of 2 to 9 carbon atoms and 1 to 2 nitrogen atoms and/or an oxygen or a sulfur atom, where each of said aromatic substituents may in turn be substituted with one or two alkyls of 1 to 6 carbon atoms, halogen, hydroxyl, trifluoromethyl, halophenyl or alkoxy of 1 to 3 carbon atoms; and non-toxic, pharmacologically acceptable salts thereof formed with inorganic or organic bases; the compounds as well as their salts are useful as analgesics, antipyretics, antithrombotic and antiphlogistics.

  该公式化合物的化合物为##STR1##其中R.sub.1为氢、卤素或1至3个碳原子的烷基；R.sub.2为氢或1至3个碳原子的烷基；R.sub.3为6至10个碳原子的芳香烃基或2至9个碳原子和1至2个氮原子和/或氧或硫原子的芳香杂环，其中每个芳香取代基可以被1至6个碳原子的烷基、卤素、羟基、三氟甲基、卤苯基或1至3个碳原子的烷氧基取代；以及与无机或有机碱形成的非毒性、药理学可接受的盐；这些化合物及其盐可用作镇痛剂、退热剂、抗血栓和抗炎药。
• Antiulcer thiazol-2-ylcarbamoyl-carboxylic acids, esters and amides
  申请人：Pfizer Inc.

  公开号：US04321372A1

  公开（公告）日：1982-03-23

  This invention encompasses orally effective antiulcer agents of the formula ##STR1## wherein X is hydroxy, (C.sub.1 -C.sub.5)-alkoxy, phenoxy, benzyloxy, or --NH(CH.sub.2).sub.n Y wherein n is an integer of value 2 to 4 and Y is di-(C.sub.1 -C.sub.3)-alkylamino, 1-pyrrolidinyl, 1-piperidinyl or 4-morpholinyl; R' and R" when taken together are (C.sub.3 -C.sub.8)-alkylene, with the proviso that the ring so formed is 5- to 8-membered; R' and R" when taken separately are each independently hydrogen, (C.sub.1 -C.sub.6)-alkyl or (C.sub.5 -C.sub.6)-cycloalkyl, with the proviso that when X is other than --NH(CH.sub.2).sub.n Y, at least one of R' and R" is other than hydrogen; the pharmaceutically acceptable cationic salts thereof when X is hydroxyl, and the pharmaceutically acceptable anionic salts thereof when X is --NH(CH.sub.2).sub.n Y.

  这项发明涵盖了以下结构的口服抗溃疡药物：##STR1## 其中 X 是羟基、(C.sub.1 -C.sub.5)-烷氧基、苯氧基、苄氧基，或--NH(CH.sub.2).sub.n Y，其中 n 是值为 2 到 4 的整数，Y 是双-(C.sub.1 -C.sub.3)-烷基氨基、1-吡咯啉基、1-哌啶基或 4-吗啉基；当 R' 和 R" 结合在一起时为 (C.sub.3 -C.sub.8)-烷基烯，但所形成的环为 5 至 8 个成员；当 R' 和 R" 分别取时，它们各自独立地是氢、(C.sub.1 -C.sub.6)-烷基或 (C.sub.5 -C.sub.6)-环烷基，但当 X 不是 --NH(CH.sub.2).sub.n Y 时，R' 和 R" 中至少有一个不是氢。当 X 是羟基时，其在药学上可接受的阳离子盐，当 X 是 --NH(CH.sub.2).sub.n Y 时，其在药学上可接受的阴离子盐。